Table 1. Non-CD5-T-cell marker-positive large B-cell lymphomas: literature review.
| References | Total no. of cases | No. of positive cases and subtype | T-cell marker (no. of positive/tested cases) | B-cell marker (no. of positive/tested cases) | Gene rearrangement | EBER-ISH | Detection method | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD2 | CD3 | CD4 | CD7 | CD8 | CD5 | CD20 | PAX5 | CD138 | IGH/K | TCRB/G | |||||
| Suzuki et al. | 150 | 11 DLBCL | 4/11 | 0/11 | 1/11 | 6/11 | 2/11 | 1/11 | 10/11 | NA | NA | NA | NA | 1/11 | FCM with IHC |
| Lee et al. | 1 | 1 DLBCL-E | 0 | 1 | 0 | NA | 0 | 0 | 1 | 1 | NA | 1 | 1 | 1 | IHC only |
| 2 PBL | 0/2 | 2/2 | 1/2 | 0/2 | 0/2 | 0/2 | 1/2 | 1/2 | 2/2 | 1/1 | 0/1 | 2/2 | IHC only | ||
| Oliveira et al. | 16 | 7 DLBCL-PCD | 0/7 | 7/7 | 2/7 | 0/7 | 0/7 | 0/7 | 7/7 | 7/7 | 2/2 | 7/7 | 0/7 | 1/7 | IHC only |
| 5 DLBCL-AF | 5/5 | 5/5 | 4/5 | 0/5 | 2/5 | 4/5 | 2/5 | 5/5 | NA | 4/4 | 0/4 | 0/4 | |||
| 2 BL | 0/2 | 2/2 | 0/1 | 0/1 | 0/1 | 0/2 | 2/2 | 1/1 | NA | 0/0 | 0/0 | 0/2 | |||
| Sun et al. | 1 | 1 PBL | 0 | 1 | NA | 0 | NA | 0 | 0 | 0 | 1 | NP | NP | 1 | IHC only |
| Sangle et al. | 1 | 1 DLBCL | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | NA | 0 | 0 | 0 | IHC with FCM* |
| Wang et al. | 1 | 1 PMLBL | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | IHC only |
| Suzuki et al. | 1 | 1 PBL | NA | 1 | 1 | NA | NA | NA | 0 | 0 | 1 | 1 | 0 | 1 | IHC only |
| Wang et al. | 4 | 2 DLBCL | 1/2 | 2/2 | 1/2 | 2/2 | 0/2 | 1/2 | 2/2 | 2/2 | 0/2 | 2/2 | 0/2 | 2/2 | IHC only |
| 2 PBL | 0/2 | 2/2 | 0/2 | 0/2 | 0/2 | 0/2 | 0/2 | 0/2 | 2/2 | 2/2 | 0/2 | 1/2 | |||
| Laurent et al. | 27 | 11 ALK+ DLBCL | 0/11 | 0/11 | 11/11 | NP | 0/11 | 0/11 | 1/11 | NA | 11/11 | 1/2 | NA | NA | IHC only |
| Carulli et al. | 951 | 2 DLBCL | NA | NA | NA | NA | 2/2 | NA | NA | NP | NP | NP | NP | NP | FCM only |
| Tzankov et al. | 1 | 1 PBL | NA | 0 | 1 | NA | NA | NA | NA | NA | 1 | 1 | 1 | 1 | IHC only |
| Tomita et al. | 1 | 1 PAL | 0 | 0 | 0 | 1 | 0 | 0 | 0 | NA | NA | 1 | 0 | 1 | IHC and FCM |
| Petitjean et al. | 12 | 5 PAL | 4/5 | 4/5 | 1/5 | 0/5 | 0/5 | 0/5 | 3/5 | NP | 1/4 | 1/1 | 0/1 | 5/5 | IHC only |
| Kaleem et al. | 210 | 2 DLBCL | 1/2 | 0/2 | 1/2 | 1/2 | 0/2 | 0/2 | NA | NP | NP | NP | NP | NP | FCM only |
| Inaba et al. | 128 | 1 DL | 1 | 0 | 0 | 3 | 0 | 0 | 3/4 | NP | NP | NDD | NDD | NP | FCM only |
| Beaty et al. | 1 | 1 HHV+ DLBCL | NP | 1 | NP | NP | NP | NP | 1 | NP | NP | NP | NP | 1 | IHC only |
| Mori et al. | 1 | 1 PAL | 0 | 1 | 1 | NP | 0 | 0 | 1 | NP | NP | 0 | 0 | 1 | IHC only |
| Hollingsworth et al. | 3 | 1 IDA lymphoma | 0 | 1† | 0 | 0 | 0 | 0 | 0 | NP | NP | 1 | 1 | 1 | FCM and/or IHC |
| Present series | 501 | 25 DLBCL‡ | 2/25 | 0/25 | 0/25 | 10/25 | 18/25 | 5/25 | 25/25 | NP | NP | 11/11 | 0/9 | 0/25 | FCM with IHC |
| 2 IVLBCL | 0/2 | 0/2 | 1/2 | 0/2 | 1/2 | 2/2 | 2/2 | NP | NP | 1/1 | 0/1 | 0/2 | |||
* The details of the flow cytometry result are not available; †positive by immunohistochemistry and negative by flow cytometry; ‡Cases include one patient with follicular lymphoma grade 3B and diffuse large B-cell lymphoma (DLBCL); IGH/K: immunoglobulin heavy chain/kappa light chain; TCRB/G, T-cell receptor beta chain/gamma chain; NA, not available; DLBCL-E, Epstein-Barr virus positive DLBCL of the elderly; DLBCL-PCD, DLBCL with plasmacytic differentiation; DLBCL-AF, DLBCL with anaplastic features; NP, not performed; DL, diffuse large cell lymphoma (classification according to Working Formulation); NDD, not described in detail; IDA lymphoma, immunodeficiency associated lymphoma.